Get the Stockscreener App
5.08
0.40%
0.02
Alvotech stock is traded at $5.08, with a volume of 42,223.
It is up +0.40% in the last 24 hours and down -40.38% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$5.06
Open:
$5.12
24h Volume:
42,223
Relative Volume:
0.09
Market Cap:
$1.58B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-2.7459
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-7.47%
1M Performance:
-40.38%
6M Performance:
-50.00%
1Y Performance:
-59.16%
1-Day Range:
$5.065
$5.14
1-Week Range:
$5.05
$5.49
52-Week Range:
$4.70
$13.70
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.08 | 1.58B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
118.85 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.915 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.11 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
471.95 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech and Advanz announce EC approval for Gobivaz biosimilar - Pharmaceutical Technology
Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - PR Newswire
Alvotech and Advanz win EC approval for first Simponi biosimilar - The Pharma Letter
Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar - TipRanks
Gobivaz approved across Europe as first Simponi biosimilar - PharmaTimes
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position - simplywall.st
Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar - Seeking Alpha
European Commission approves Alvotech’s biosimilar golimumab - Investing.com India
European Commission approves Alvotech’s biosimilar golimumab By Investing.com - Investing.com Canada
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - The Manila Times
Will Alvotech (Z45) stock outperform foreign stocks2025 Short Interest & Fast Gaining Stock Reports - newser.com
Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobivaz, fyrstu hliðstæðuna við Simponi - GlobeNewswire
Is Alvotech (Z45) stock attractive for growth fundsTrade Entry Report & AI Forecasted Stock Moves - newser.com
Can Alvotech (Z45) stock reach $200 price target2025 Technical Overview & Fast Momentum Entry Tips - newser.com
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent
What MACD signals say about Alvotech2025 Earnings Surprises & Weekly Return Optimization Alerts - newser.com
Using economic indicators to assess Alvotech Equity Warrant potentialJuly 2025 Summary & High Conviction Buy Zone Alerts - newser.com
Is Alvotech (Z45) stock good for long term investingWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Is Alvotech stock a smart buy before Fed meetingPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing - GlobeNewswire
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewswire Inc.
UBS Group Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
Can Alvotech Equity Warrant stock deliver surprise earnings beatWeekly Trend Recap & Technical Pattern Based Signals - newser.com
How analysts rate Alvotech stock todayWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
What technical patterns form on Alvotech (Z45) stock charts2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Alvotech Equity Warrant stock deliver shareholder valueLayoff News & Smart Investment Allocation Insights - newser.com
Trend analysis for Alvotech this weekWall Street Watch & Expert Verified Stock Movement Alerts - newser.com
UBS Maintains Alvotech (ALVO) Buy Recommendation - Nasdaq
Is Alvotech (Z45) stock a top dividend aristocrat candidateJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
UBS Maintains Buy Rating on ALVO, Lowers Price Target to $10.00 - GuruFocus
Alvotech at Jefferies London: Strategic Growth Amid Challenges By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alvotech (ALVO) And Encourages Shareholders to Reach Out - ACCESS Newswire
UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating - MarketScreener
What hedge fund activity signals for Alvotech Equity Warrant stockOptions Play & Low Drawdown Investment Ideas - newser.com
ATTENTION ALVO Shareholders: Lost Money on Alvotech? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Alvotech (ALVO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals - TipRanks
Alvotech’s Earnings Call: Growth Amid Challenges - MSN
Will Alvotech stock reach all time highs in 2025July 2025 Update & Daily Entry Point Alerts - newser.com
Why Alvotech stock could outperform in 2025Quarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Will Alvotech stock benefit from AI adoptionJuly 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
How Alvotech (Z45) stock trades under stagflationM&A Rumor & Safe Entry Zone Identification - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alvotech (ALVO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Alvotech (ICSE:ALVO) Price Target Decreased by 35.59% to 1,409.50 - Nasdaq
Applying chart zones and confluence areas to AlvotechJuly 2025 Review & Consistent Profit Trade Alerts - newser.com
Detecting price anomalies in Alvotech Equity Warrant with AIMarket Trend Summary & Community Verified Trade Signals - newser.com
Risk adjusted return profile for Alvotech analyzedTrade Volume Summary & Free Growth Oriented Trading Recommendations - newser.com
2025-11-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alvotech (ALVO) and Encourages Investors to Learn More About the Investigation | NDAQ:ALVO | Press Release - Stockhouse
Is Alvotech stock affected by interest rate hikesQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):